Vanguard Capital Management
PHAT icon

Vanguard Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Vanguard Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.8M Buy
2,656,944
+73,308
+3% +$836K ﹤0.01% 2248
2026
Q1 		$28.7M Buy
+2,583,636
New +$32.6M ﹤0.01% 2156

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Capital Management's PHAT Position: Q2 2026 in Review

Vanguard Capital Management increased its Phathom Pharmaceuticals (PHAT) stake by 2.8% in Q2 2026, buying an estimated $836K and bringing the position to 2,656,944 shares worth $28.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2248.

Vanguard Capital Management first reported a position in PHAT in Q1 2026 and has held it in 2 quarters since. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Vanguard Capital Management held 2,656,944 shares of Phathom Pharmaceuticals worth $28.8M as of Q2 2026.
  • Vanguard Capital Management bought 73,308 Phathom Pharmaceuticals shares in Q2 2026, an estimated $836K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2248 holding.
  • Vanguard Capital Management first reported a position in Phathom Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.